ORION CORPORATION PRESS RELEASE
Orion Animal Health’s Bonqat® (pregabalin) receives positive CVMP opinion
The compound is recommended for alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats. The final decision of the
Pregabalin is a new active substance for veterinary use and it acts in the central nervous system by reducing the release of various neurotransmitters (glutamate and monoaminergic neurotransmitters), resulting in an anxiolytic effect.
Orion has also submitted a new animal drug application for pregabalin to the
Contact person:
tel. +358 10 426 4116
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to
© OMX, source